Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Recent Patents on Anti-Cancer Drug Discovery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 20594185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia

  2012cited by this paper
• Ofatumumab, a human anti-CD20 monoclonal antibody.

  2010cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• Antibody-based therapy of leukaemia

  2009cited by this paper
• Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

  2009cited by this paper
• Production of therapeutic antibodies with controlled fucosylation

  2009cited by this paper
• Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

  2009cited by this paper
• First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

  2008cited by this paper
• Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis

  2008cited by this paper
• Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.

  2008cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.

  2008cited by this paper
• The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

  2006cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

  2006cited by this paper
• FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling.

  2005cited by this paper
• Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

  2005cited by this paper
• Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

  2005cited by this paper
• Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

  2005cited by this paper
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005cited by this paper
• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  2005cited by this paper
• Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab

  2004cited by this paper
• Rituximab as Treatment for Refractory Kidney Transplant Rejection

  2004cited by this paper
• SNPs in cancer research and treatment

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Generation and production of engineered antibodies

  2004cited by this paper
• FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

  2003cited by this paper
• Analysis of Fc gamma receptor II (CD32) polymorphism in populations of African and South Asian ancestry reveals east-west geographic gradients of allele frequencies.

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Pharmacogenetic aspects in treatment of colorectal cancer--an update.

  2003cited by this paper
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002cited by this paper
• Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Genomic organization of classical human low-affinity Fcgamma receptor genes.

  2002cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease.

  2002cited by this paper
• IgG Fc receptors.

  2001cited by this paper
• Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.

  2001cited by this paper
• FcγRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients

  2001cited by this paper
• Functional CD32 molecules on human NK cells.

  1999cited by this paper
• Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

  1998cited by this paper
• Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene.

  1998cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

  1997cited by this paper
• Molecular basis for a familial defect in phagocyte expression of IgG receptor I (CD64).

  1995cited by this paper
• Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.

  1993cited by this paper
• The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event.

  1993cited by this paper
• A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

  1991cited by this paper
• Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities.

  1990cited by this paper
• Structure and function of human and murine receptors for IgG.

  1988cited by this paper

• A shark VNAR-IL-15 fusion protein that suppresses TROP2+ tumor growth.

  2026cites this paper
• Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

  2017cites this paper
• Fcγ Receptor Heterogeneity in Leukocyte Functional Responses

  2017cites this paper
• Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities.

  2016cites this paper
• Immunological boosting and personalization of oncolytic virotherapies for cancer treatment

  2016cites this paper
• Études des interactions entre les immunoglobulines G et leurs récepteurs Fc gamma afin d'évaluer le patron de glycosylation des anticorps

  2016cites this paper
• Functional specialization and cooperation between the neonatal-and classical IgG receptors , FcRn and

  2014cites this paper
• FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

  2014cites this paper
• Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects.

  2014cites this paper
• Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

  2012cites this paper